Back

Agreement between manual and AI-enhanced echocardiographic assessment of cancer therapy-related cardiac dysfunction in patients with early breast cancer

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Eivind Orstad

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

6 More presentations in this session

Presentation thumbnail
Baseline early diastolic mitral annular velocities and cancer therapy related cardiac dysfunction in HER2 therapy
Mr A. Chowdhury (Clayton, AU)
Abstract Slides
Presentation thumbnail
Incremental value of TAPSE added to HFA-ICOS for ESC-Defined Cancer Therapy–Related Cardiac Dysfunction
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence and severity of cancer-therapy-related cardiac dysfunction during contemporary breast cancer therapy in a real-world cohort
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Machine learning-driven probability of cancer therapy–related cardiac dysfunction in patients with non-Hodgkin lymphoma
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Cardiopulmonary fitness and cancer therapy-related cardiac dysfunction defined by CMR: insights from the EMBRACE-MRI study
Doctor T. Goncalves (Toronto, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
From imaging to action: improving heart failure care in cardio-oncology
20 June 2025
thumbnail
Congress Presentation
Effects of sacubitril/valsartan on left and right ventricular function during and after breast cancer therapy: a randomised placebo-controlled trial
29 August 2026
thumbnail
Congress Presentation
Artificial intelligence–enhanced electrocardiography for detection of subclinical left ventricular dysfunction in cancer survivors
28 August 2026
thumbnail
Congress Presentation
Use of artificial intelligence for the automatic assessment of left ventricular ejection fraction by oncology staff in chemotherapy patients
11 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources